Contact this trialFirst, we need to learn more about you.
NMDA Receptor Antagonist
Ketamine + Esketamine for Depression
Recruiting5 awardsPhase 4
Boston, Massachusetts
This trialwill examine outcomes of patients with depression and suicidal ideation who receive IV ketamine & IN esketamine compared to a historical group. Patients will get 8 IV ketamine treatments, 13 esketamine visits & daily surveys. It will look at feasibility, tolerability & efficacy of the treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.